Irbesartan
- Generic Name
- Irbesartan
- Brand Names
- Avalide, Avapro, Ifirmacombi, Karvea, Karvezide, Irbesartan Teva, Ifirmasta (previously Irbesartan Krka), Irbesartan Zentiva (previously Irbesartan Winthrop), Aprovel
- Drug Type
- Small Molecule
- Chemical Formula
- C25H28N6O
- CAS Number
- 138402-11-6
- Unique Ingredient Identifier
- J0E2756Z7N
- Background
Irbesartan is an angiotensin receptor blocker (ARB) indicated to treat hypertension or diabetic nephropathy. It can also be used as part of a combination product with hydrochlorothiazide for patients not well controlled or not expected to be well controlled on monotherapy. Unlike angiotensin converting enzyme inhibitors, ARBs are not associated with a dry co...
- Indication
Irbesartan is indicated to treat hypertension and diabetic nephropathy in hypertensive patients with type 2 diabetes, elevated serum creatinine, and proteinuria. A combination product with hydrochlorothiazide is indicated for hypertension in patients with uncontrolled hypertension with monotherapy or first line in patients not expected to be well controlled ...
- Associated Conditions
- Diabetic Nephropathy, Hypertension
- Associated Therapies
- -
Clinical Trial of Keluoxin Capsules in the Treatment of Diabetic Kidney Disease with Diabetic Retinopathy
- Conditions
- Interventions
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 460
- Registration Number
- NCT06660940
A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Hansoh BioMedical R&D Company
- Target Recruit Count
- 90
- Registration Number
- NCT06635772
Pharmacokinetics of Irbesartan/Amlodipine High FDC and Co-administration of Irbesartan and Amlodipine High in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT05688098
- Locations
- 🇰🇷
H Plus Yangji Hospital, Seoul, Korea, Republic of
Pharmacokinetics of Irbesartan/Amlodipine FDC and Co-administration of Irbesartan and Amlodipine in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT05663073
- Locations
- 🇰🇷
H Plus Yangji Hospital, Seoul, Korea, Republic of
Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients
- Conditions
- Interventions
- First Posted Date
- 2022-07-27
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 271
- Registration Number
- NCT05476354
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
Clinical Efficacy and Safety Evaluation of Irbesartan High and Amlodipine Combined Therapy in Essential Hypertension Patients
- Conditions
- Interventions
- First Posted Date
- 2022-07-27
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 157
- Registration Number
- NCT05475665
- Locations
- 🇰🇷
Hanyang University Seoul Hospital, Seoul, Korea, Republic of
Sacubitril/Valsartan for CKD5 Stage Dialysis Patients
- Conditions
- Interventions
- First Posted Date
- 2022-02-16
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 330
- Registration Number
- NCT05243199
- Locations
- 🇨🇳
Department of Nephrology, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, Shanghai, China
A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
- Conditions
- Interventions
- First Posted Date
- 2021-09-24
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 716
- Registration Number
- NCT05056727
- Locations
- 🇻🇳
Research Site, Hue, Vietnam
Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?
- Conditions
- Interventions
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 341
- Registration Number
- NCT04606563
- Locations
- 🇨🇦
Royal Jubilee Hospital, Nanaimo, British Columbia, Canada
🇨🇦St Paul's Hospital, Vancouver, British Columbia, Canada
🇨🇦The Ottawa Hospital, Ottawa, Ontario, Canada
A Study to Evaluate ALN-AGT01 in Patients With Hypertension
- Conditions
- Interventions
- First Posted Date
- 2019-05-01
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 124
- Registration Number
- NCT03934307
- Locations
- 🇬🇧
Clinical Trial Site, Manchester, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.